HOW TO AVOID GLUCOSE DEGRADATION PRODUCTS IN PERITONEAL DIALYSIS FLUIDS
Corporate Research, 1 Gambro AB; Analytical Chemistry, 2 University of Lund, Lund, Sweden Correspondence to: M. Erixon, Gambro Lundia AB, Box 10101, S-220 10 Lund, Sweden. martin.erixon{at}gambro.com Objective: The formation of glucose degradation products (GDPs) during sterilization of peritoneal d...
Gespeichert in:
Veröffentlicht in: | Peritoneal Dialysis International 2006-07, Vol.26 (4), p.490-497 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 497 |
---|---|
container_issue | 4 |
container_start_page | 490 |
container_title | Peritoneal Dialysis International |
container_volume | 26 |
creator | Erixon, Martin Wieslander, Anders Linden, Torbjorn Carlsson, Ola Forsback, Gunita Svensson, Eva Jonsson, Jan Ake Kjellstrand, Per |
description | Corporate Research, 1 Gambro AB; Analytical
Chemistry, 2 University of Lund, Lund, Sweden
Correspondence to: M. Erixon, Gambro Lundia AB, Box 10101, S-220 10 Lund,
Sweden.
martin.erixon{at}gambro.com
Objective: The formation of glucose degradation
products (GDPs) during sterilization of peritoneal dialysis fluids (PDFs) is
one of the most important aspects of biocompatibility of glucose-containing
PDFs. Producers of PDFs are thus trying to minimize the level of GDPs in their
products. 3,4-Dideoxyglucosone-3-ene (3,4-DGE) has been identified as the most
bioreactive GDP in PDFs. It exists in a temperature-dependent equilibrium with
a pool of 3-deoxyglucosone (3-DG) and is a precursor in the irreversible
formation of 5-hydroxymethyl furaldehyde (5-HMF). The aim of the present study
was to investigate how to minimize GDPs in PDFs and how different
manufacturers have succeeded in doing so.
Design: Glucose solutions at different pHs and
concentrations were heat sterilized and 3-DG, 3,4-DGE, 5-HMF, formaldehyde,
and acetaldehyde were analyzed. Conventional as well as biocompatible fluids
from different manufacturers were analyzed in parallel for GDP
concentrations.
Results: The concentrations of 3-DG and 3,4-DGE
produced during heat sterilization decreased when pH was reduced to about 2.
Concentration of 5-HMF decreased when pH was reduced to 2.6. After further
decrease to a pH of 2.0, concentration of 5-HMF increased slightly, and below
a pH of 2.0 it increased considerably, together with formaldehyde; 3-DG
continued to drop and 3,4-DGE remained constant. Inhibition of cell growth was
paralleled by 3,4-DGE concentration at pH 2.0 6.0. A high glucose
concentration lowered concentrations of 3,4-DGE and 3-DG at pH 5.5 and of
5-HMF at pH 1. At pH 2.2 and 3.2, glucose concentration had a minor effect on
the formation of GDPs. All conventional PDFs contained high levels of 3,4-DGE
and 3-DG. Concentrations were considerably lower in the biocompatible fluids.
However, the concentration of 5-HMF was slightly higher in all the
biocompatible fluids.
Conclusion: The best way to avoid reactive GDPs is to
have a pH between 2.0 and 2.6 during sterilization. If pHs outside this range
are used, it becomes more important to have high glucose concentration during
the sterilization process. There are large variations in GDPs, both within and
between biocompatible and conventionally manufactured PDFs.
KEY WORDS: 3,4-DGE; glucose degradation products; cytotoxicity; pH; glucose; PD |
doi_str_mv | 10.1177/089686080602600414 |
format | Article |
fullrecord | <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_proquest_miscellaneous_68703338</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68703338</sourcerecordid><originalsourceid>FETCH-LOGICAL-c444t-ea81ad9455df361bdee021fab36882f27f6d93bfd7c5ec02503e96abacd02c933</originalsourceid><addsrcrecordid>eNplkU9vm0AQxVdRq8RJ-gV6qLg0N9rZP-wuR2SIg4RCZXCqnlYL7DZEOHZYI5Rv37VstYcenmYOv3kzmofQZwzfMBbiO8iYSw4SOBAOwDC7QAsssAwZBfYBLY5AeCSu0LVzLwCUUBCX6ApzKTFl0QKtHsqfQV0GyVOZp8Gq2CzLKgvSbLVO0qTOy8fgx7pMN8u6CnLfZ-u8Lh-zpAjSPCl-VXkV3BebPK1u0UerB2c-nesN2txn9fIhLMpVvkyKsGWMHUKjJdZdzKKos5TjpjMGCLa6of4iYomwvItpYzvRRqYFEgE1MdeNbjsgbUzpDSpOvm42-6lR-7Hf6vFd7XSvhmnv1XgpZ5QAa0lDhYqNxIpZwpWOKFeCUhoRKiLLwNvdnez24-5tMu6gtr1rzTDoV7ObnOJSgOelB8kJbMedc6OxfzdjUMc01P9p-KEvZ_ep2Zru38j5_R74egKe-9_Pcz8a5bZ6GDxO1DzP_mSmWAz0D8-cif8</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68703338</pqid></control><display><type>article</type><title>HOW TO AVOID GLUCOSE DEGRADATION PRODUCTS IN PERITONEAL DIALYSIS FLUIDS</title><source>Access via SAGE</source><source>MEDLINE</source><creator>Erixon, Martin ; Wieslander, Anders ; Linden, Torbjorn ; Carlsson, Ola ; Forsback, Gunita ; Svensson, Eva ; Jonsson, Jan Ake ; Kjellstrand, Per</creator><creatorcontrib>Erixon, Martin ; Wieslander, Anders ; Linden, Torbjorn ; Carlsson, Ola ; Forsback, Gunita ; Svensson, Eva ; Jonsson, Jan Ake ; Kjellstrand, Per</creatorcontrib><description>Corporate Research, 1 Gambro AB; Analytical
Chemistry, 2 University of Lund, Lund, Sweden
Correspondence to: M. Erixon, Gambro Lundia AB, Box 10101, S-220 10 Lund,
Sweden.
martin.erixon{at}gambro.com
Objective: The formation of glucose degradation
products (GDPs) during sterilization of peritoneal dialysis fluids (PDFs) is
one of the most important aspects of biocompatibility of glucose-containing
PDFs. Producers of PDFs are thus trying to minimize the level of GDPs in their
products. 3,4-Dideoxyglucosone-3-ene (3,4-DGE) has been identified as the most
bioreactive GDP in PDFs. It exists in a temperature-dependent equilibrium with
a pool of 3-deoxyglucosone (3-DG) and is a precursor in the irreversible
formation of 5-hydroxymethyl furaldehyde (5-HMF). The aim of the present study
was to investigate how to minimize GDPs in PDFs and how different
manufacturers have succeeded in doing so.
Design: Glucose solutions at different pHs and
concentrations were heat sterilized and 3-DG, 3,4-DGE, 5-HMF, formaldehyde,
and acetaldehyde were analyzed. Conventional as well as biocompatible fluids
from different manufacturers were analyzed in parallel for GDP
concentrations.
Results: The concentrations of 3-DG and 3,4-DGE
produced during heat sterilization decreased when pH was reduced to about 2.
Concentration of 5-HMF decreased when pH was reduced to 2.6. After further
decrease to a pH of 2.0, concentration of 5-HMF increased slightly, and below
a pH of 2.0 it increased considerably, together with formaldehyde; 3-DG
continued to drop and 3,4-DGE remained constant. Inhibition of cell growth was
paralleled by 3,4-DGE concentration at pH 2.0 6.0. A high glucose
concentration lowered concentrations of 3,4-DGE and 3-DG at pH 5.5 and of
5-HMF at pH 1. At pH 2.2 and 3.2, glucose concentration had a minor effect on
the formation of GDPs. All conventional PDFs contained high levels of 3,4-DGE
and 3-DG. Concentrations were considerably lower in the biocompatible fluids.
However, the concentration of 5-HMF was slightly higher in all the
biocompatible fluids.
Conclusion: The best way to avoid reactive GDPs is to
have a pH between 2.0 and 2.6 during sterilization. If pHs outside this range
are used, it becomes more important to have high glucose concentration during
the sterilization process. There are large variations in GDPs, both within and
between biocompatible and conventionally manufactured PDFs.
KEY WORDS: 3,4-DGE; glucose degradation products; cytotoxicity; pH; glucose; PD fluids; bioreactive.
Received 7 November 2005;
accepted 3 February 2006.</description><identifier>ISSN: 0896-8608</identifier><identifier>ISSN: 1718-4304</identifier><identifier>EISSN: 1718-4304</identifier><identifier>DOI: 10.1177/089686080602600414</identifier><identifier>PMID: 16881345</identifier><language>eng</language><publisher>United States</publisher><subject>4-DGE ; Animals ; bioreactive ; Cell Division ; Clinical Medicine ; cytotoxicity ; Dialysis Solutions - analysis ; Dialysis Solutions - chemistry ; Dialysis Solutions - classification ; fluids ; glucose ; Glucose - analogs & derivatives ; Glucose - analysis ; Glucose - metabolism ; glucose degradation products ; Humans ; Hydrogen-Ion Concentration ; Klinisk medicin ; L Cells ; Medical and Health Sciences ; Medicin och hälsovetenskap ; Mice ; Peritoneal Dialysis - methods ; Urologi och njurmedicin ; Urology and Nephrology</subject><ispartof>Peritoneal Dialysis International, 2006-07, Vol.26 (4), p.490-497</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c444t-ea81ad9455df361bdee021fab36882f27f6d93bfd7c5ec02503e96abacd02c933</citedby><cites>FETCH-LOGICAL-c444t-ea81ad9455df361bdee021fab36882f27f6d93bfd7c5ec02503e96abacd02c933</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16881345$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://lup.lub.lu.se/record/399022$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Erixon, Martin</creatorcontrib><creatorcontrib>Wieslander, Anders</creatorcontrib><creatorcontrib>Linden, Torbjorn</creatorcontrib><creatorcontrib>Carlsson, Ola</creatorcontrib><creatorcontrib>Forsback, Gunita</creatorcontrib><creatorcontrib>Svensson, Eva</creatorcontrib><creatorcontrib>Jonsson, Jan Ake</creatorcontrib><creatorcontrib>Kjellstrand, Per</creatorcontrib><title>HOW TO AVOID GLUCOSE DEGRADATION PRODUCTS IN PERITONEAL DIALYSIS FLUIDS</title><title>Peritoneal Dialysis International</title><addtitle>Perit Dial Int</addtitle><description>Corporate Research, 1 Gambro AB; Analytical
Chemistry, 2 University of Lund, Lund, Sweden
Correspondence to: M. Erixon, Gambro Lundia AB, Box 10101, S-220 10 Lund,
Sweden.
martin.erixon{at}gambro.com
Objective: The formation of glucose degradation
products (GDPs) during sterilization of peritoneal dialysis fluids (PDFs) is
one of the most important aspects of biocompatibility of glucose-containing
PDFs. Producers of PDFs are thus trying to minimize the level of GDPs in their
products. 3,4-Dideoxyglucosone-3-ene (3,4-DGE) has been identified as the most
bioreactive GDP in PDFs. It exists in a temperature-dependent equilibrium with
a pool of 3-deoxyglucosone (3-DG) and is a precursor in the irreversible
formation of 5-hydroxymethyl furaldehyde (5-HMF). The aim of the present study
was to investigate how to minimize GDPs in PDFs and how different
manufacturers have succeeded in doing so.
Design: Glucose solutions at different pHs and
concentrations were heat sterilized and 3-DG, 3,4-DGE, 5-HMF, formaldehyde,
and acetaldehyde were analyzed. Conventional as well as biocompatible fluids
from different manufacturers were analyzed in parallel for GDP
concentrations.
Results: The concentrations of 3-DG and 3,4-DGE
produced during heat sterilization decreased when pH was reduced to about 2.
Concentration of 5-HMF decreased when pH was reduced to 2.6. After further
decrease to a pH of 2.0, concentration of 5-HMF increased slightly, and below
a pH of 2.0 it increased considerably, together with formaldehyde; 3-DG
continued to drop and 3,4-DGE remained constant. Inhibition of cell growth was
paralleled by 3,4-DGE concentration at pH 2.0 6.0. A high glucose
concentration lowered concentrations of 3,4-DGE and 3-DG at pH 5.5 and of
5-HMF at pH 1. At pH 2.2 and 3.2, glucose concentration had a minor effect on
the formation of GDPs. All conventional PDFs contained high levels of 3,4-DGE
and 3-DG. Concentrations were considerably lower in the biocompatible fluids.
However, the concentration of 5-HMF was slightly higher in all the
biocompatible fluids.
Conclusion: The best way to avoid reactive GDPs is to
have a pH between 2.0 and 2.6 during sterilization. If pHs outside this range
are used, it becomes more important to have high glucose concentration during
the sterilization process. There are large variations in GDPs, both within and
between biocompatible and conventionally manufactured PDFs.
KEY WORDS: 3,4-DGE; glucose degradation products; cytotoxicity; pH; glucose; PD fluids; bioreactive.
Received 7 November 2005;
accepted 3 February 2006.</description><subject>4-DGE</subject><subject>Animals</subject><subject>bioreactive</subject><subject>Cell Division</subject><subject>Clinical Medicine</subject><subject>cytotoxicity</subject><subject>Dialysis Solutions - analysis</subject><subject>Dialysis Solutions - chemistry</subject><subject>Dialysis Solutions - classification</subject><subject>fluids</subject><subject>glucose</subject><subject>Glucose - analogs & derivatives</subject><subject>Glucose - analysis</subject><subject>Glucose - metabolism</subject><subject>glucose degradation products</subject><subject>Humans</subject><subject>Hydrogen-Ion Concentration</subject><subject>Klinisk medicin</subject><subject>L Cells</subject><subject>Medical and Health Sciences</subject><subject>Medicin och hälsovetenskap</subject><subject>Mice</subject><subject>Peritoneal Dialysis - methods</subject><subject>Urologi och njurmedicin</subject><subject>Urology and Nephrology</subject><issn>0896-8608</issn><issn>1718-4304</issn><issn>1718-4304</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNplkU9vm0AQxVdRq8RJ-gV6qLg0N9rZP-wuR2SIg4RCZXCqnlYL7DZEOHZYI5Rv37VstYcenmYOv3kzmofQZwzfMBbiO8iYSw4SOBAOwDC7QAsssAwZBfYBLY5AeCSu0LVzLwCUUBCX6ApzKTFl0QKtHsqfQV0GyVOZp8Gq2CzLKgvSbLVO0qTOy8fgx7pMN8u6CnLfZ-u8Lh-zpAjSPCl-VXkV3BebPK1u0UerB2c-nesN2txn9fIhLMpVvkyKsGWMHUKjJdZdzKKos5TjpjMGCLa6of4iYomwvItpYzvRRqYFEgE1MdeNbjsgbUzpDSpOvm42-6lR-7Hf6vFd7XSvhmnv1XgpZ5QAa0lDhYqNxIpZwpWOKFeCUhoRKiLLwNvdnez24-5tMu6gtr1rzTDoV7ObnOJSgOelB8kJbMedc6OxfzdjUMc01P9p-KEvZ_ep2Zru38j5_R74egKe-9_Pcz8a5bZ6GDxO1DzP_mSmWAz0D8-cif8</recordid><startdate>20060701</startdate><enddate>20060701</enddate><creator>Erixon, Martin</creator><creator>Wieslander, Anders</creator><creator>Linden, Torbjorn</creator><creator>Carlsson, Ola</creator><creator>Forsback, Gunita</creator><creator>Svensson, Eva</creator><creator>Jonsson, Jan Ake</creator><creator>Kjellstrand, Per</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>ADTPV</scope><scope>AOWAS</scope><scope>D95</scope></search><sort><creationdate>20060701</creationdate><title>HOW TO AVOID GLUCOSE DEGRADATION PRODUCTS IN PERITONEAL DIALYSIS FLUIDS</title><author>Erixon, Martin ; Wieslander, Anders ; Linden, Torbjorn ; Carlsson, Ola ; Forsback, Gunita ; Svensson, Eva ; Jonsson, Jan Ake ; Kjellstrand, Per</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c444t-ea81ad9455df361bdee021fab36882f27f6d93bfd7c5ec02503e96abacd02c933</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>4-DGE</topic><topic>Animals</topic><topic>bioreactive</topic><topic>Cell Division</topic><topic>Clinical Medicine</topic><topic>cytotoxicity</topic><topic>Dialysis Solutions - analysis</topic><topic>Dialysis Solutions - chemistry</topic><topic>Dialysis Solutions - classification</topic><topic>fluids</topic><topic>glucose</topic><topic>Glucose - analogs & derivatives</topic><topic>Glucose - analysis</topic><topic>Glucose - metabolism</topic><topic>glucose degradation products</topic><topic>Humans</topic><topic>Hydrogen-Ion Concentration</topic><topic>Klinisk medicin</topic><topic>L Cells</topic><topic>Medical and Health Sciences</topic><topic>Medicin och hälsovetenskap</topic><topic>Mice</topic><topic>Peritoneal Dialysis - methods</topic><topic>Urologi och njurmedicin</topic><topic>Urology and Nephrology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Erixon, Martin</creatorcontrib><creatorcontrib>Wieslander, Anders</creatorcontrib><creatorcontrib>Linden, Torbjorn</creatorcontrib><creatorcontrib>Carlsson, Ola</creatorcontrib><creatorcontrib>Forsback, Gunita</creatorcontrib><creatorcontrib>Svensson, Eva</creatorcontrib><creatorcontrib>Jonsson, Jan Ake</creatorcontrib><creatorcontrib>Kjellstrand, Per</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>SwePub</collection><collection>SwePub Articles</collection><collection>SWEPUB Lunds universitet</collection><jtitle>Peritoneal Dialysis International</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Erixon, Martin</au><au>Wieslander, Anders</au><au>Linden, Torbjorn</au><au>Carlsson, Ola</au><au>Forsback, Gunita</au><au>Svensson, Eva</au><au>Jonsson, Jan Ake</au><au>Kjellstrand, Per</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>HOW TO AVOID GLUCOSE DEGRADATION PRODUCTS IN PERITONEAL DIALYSIS FLUIDS</atitle><jtitle>Peritoneal Dialysis International</jtitle><addtitle>Perit Dial Int</addtitle><date>2006-07-01</date><risdate>2006</risdate><volume>26</volume><issue>4</issue><spage>490</spage><epage>497</epage><pages>490-497</pages><issn>0896-8608</issn><issn>1718-4304</issn><eissn>1718-4304</eissn><abstract>Corporate Research, 1 Gambro AB; Analytical
Chemistry, 2 University of Lund, Lund, Sweden
Correspondence to: M. Erixon, Gambro Lundia AB, Box 10101, S-220 10 Lund,
Sweden.
martin.erixon{at}gambro.com
Objective: The formation of glucose degradation
products (GDPs) during sterilization of peritoneal dialysis fluids (PDFs) is
one of the most important aspects of biocompatibility of glucose-containing
PDFs. Producers of PDFs are thus trying to minimize the level of GDPs in their
products. 3,4-Dideoxyglucosone-3-ene (3,4-DGE) has been identified as the most
bioreactive GDP in PDFs. It exists in a temperature-dependent equilibrium with
a pool of 3-deoxyglucosone (3-DG) and is a precursor in the irreversible
formation of 5-hydroxymethyl furaldehyde (5-HMF). The aim of the present study
was to investigate how to minimize GDPs in PDFs and how different
manufacturers have succeeded in doing so.
Design: Glucose solutions at different pHs and
concentrations were heat sterilized and 3-DG, 3,4-DGE, 5-HMF, formaldehyde,
and acetaldehyde were analyzed. Conventional as well as biocompatible fluids
from different manufacturers were analyzed in parallel for GDP
concentrations.
Results: The concentrations of 3-DG and 3,4-DGE
produced during heat sterilization decreased when pH was reduced to about 2.
Concentration of 5-HMF decreased when pH was reduced to 2.6. After further
decrease to a pH of 2.0, concentration of 5-HMF increased slightly, and below
a pH of 2.0 it increased considerably, together with formaldehyde; 3-DG
continued to drop and 3,4-DGE remained constant. Inhibition of cell growth was
paralleled by 3,4-DGE concentration at pH 2.0 6.0. A high glucose
concentration lowered concentrations of 3,4-DGE and 3-DG at pH 5.5 and of
5-HMF at pH 1. At pH 2.2 and 3.2, glucose concentration had a minor effect on
the formation of GDPs. All conventional PDFs contained high levels of 3,4-DGE
and 3-DG. Concentrations were considerably lower in the biocompatible fluids.
However, the concentration of 5-HMF was slightly higher in all the
biocompatible fluids.
Conclusion: The best way to avoid reactive GDPs is to
have a pH between 2.0 and 2.6 during sterilization. If pHs outside this range
are used, it becomes more important to have high glucose concentration during
the sterilization process. There are large variations in GDPs, both within and
between biocompatible and conventionally manufactured PDFs.
KEY WORDS: 3,4-DGE; glucose degradation products; cytotoxicity; pH; glucose; PD fluids; bioreactive.
Received 7 November 2005;
accepted 3 February 2006.</abstract><cop>United States</cop><pmid>16881345</pmid><doi>10.1177/089686080602600414</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0896-8608 |
ispartof | Peritoneal Dialysis International, 2006-07, Vol.26 (4), p.490-497 |
issn | 0896-8608 1718-4304 1718-4304 |
language | eng |
recordid | cdi_proquest_miscellaneous_68703338 |
source | Access via SAGE; MEDLINE |
subjects | 4-DGE Animals bioreactive Cell Division Clinical Medicine cytotoxicity Dialysis Solutions - analysis Dialysis Solutions - chemistry Dialysis Solutions - classification fluids glucose Glucose - analogs & derivatives Glucose - analysis Glucose - metabolism glucose degradation products Humans Hydrogen-Ion Concentration Klinisk medicin L Cells Medical and Health Sciences Medicin och hälsovetenskap Mice Peritoneal Dialysis - methods Urologi och njurmedicin Urology and Nephrology |
title | HOW TO AVOID GLUCOSE DEGRADATION PRODUCTS IN PERITONEAL DIALYSIS FLUIDS |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T17%3A42%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=HOW%20TO%20AVOID%20GLUCOSE%20DEGRADATION%20PRODUCTS%20IN%20PERITONEAL%20DIALYSIS%20FLUIDS&rft.jtitle=Peritoneal%20Dialysis%20International&rft.au=Erixon,%20Martin&rft.date=2006-07-01&rft.volume=26&rft.issue=4&rft.spage=490&rft.epage=497&rft.pages=490-497&rft.issn=0896-8608&rft.eissn=1718-4304&rft_id=info:doi/10.1177/089686080602600414&rft_dat=%3Cproquest_swepu%3E68703338%3C/proquest_swepu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68703338&rft_id=info:pmid/16881345&rfr_iscdi=true |